🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Read the article featured on the November cover— VISTA Expression on Cancer-Associated Endothelium Selectively Prevents #Tcell Extravasation, by Sietse J. Luk, Mirjam H.M. Heemskerk et al. bit.ly/3Mt1dxN Max Grönloh Noel F. de Miranda #CancerImmunology

Absolutely brilliant concept: pre-treatment banking of blood samples prior to starting immunotherapy, then analyzing scRNAseq of prospective blood and tissue if pt develops irAE. Dr. Villani identifying immune cell subsets contributing to irAE. SITC Care #SITC23

VEGFR2 is expressed on Tregs in patients with cholangiocarcinoma, and signaling through VEGFR2 is critical to immunotherapy response in animal models of CCA. Great work by Mohamed-Reda Benmebarak. Society for Immunotherapy of Cancer #SITC23

New #JITC article: CD8+ chimeric antigen receptor T cells manufactured in absence of CD4+ cells exhibit hypofunctional phenotype bit.ly/3uikEmL

I’m a dedicated T cell girl, but Tullia Bruno, PhD has an amazing way of getting an audience excited about B cells and TLS! They are the most abundant cells in solid tumors. Not all B cells are created equal. B cells and TLS are transcriptionally and locationally distinct.

Congrats to our fantastic residents at @CaseUHmed on another incredible match. Best day of the year seeing peoples hard work pay off! Shout out to the OG @keitharmitage #thematch

Dr. Nancy Kemeny, a leading oncologist and #HAItherapy pioneer, recently joined COLONTOWN to share her expertise with patients with colorectal cancer liver metastases. Watch the video: buff.ly/3sYfOek #coloncancer #livermets #Hepaticarteryinfusion #HAIpump

CheckMate-8HW Meets Primary End Points With Nivolumab/Ipilimumab in mCRC targetedonc.com/view/checkmate… via @targetedonc #colorectal #cancer #immunotherapy Bristol Myers Squibb #CancerResearch #MSI-high #clinicaltrials

Early onset GI cancers will be highlighted at ASCO #GI24 EO-EGC is rising along with CRC. Our results in JNCI show EO-EGC is: ⬆️gastric ⬆️diffuse type 🟰 stage/survival Much still unknown Fantastic collaboration Andrea Cercek Yelena Y. Janjigian MD Steve Maron Memorial Sloan Kettering Cancer Center

🙏🏻 Kimmie Ng, MD, MPH for sharing our work Eric Lander, MD Vanderbilt University Medical Center @VUMC_Cancer on #earlyonset #ColorectalCancer during your excellent KeyNote Lecture at ASCO #GI24. We are proud of our ongoing work. 💙 #crcsm #cancer #CancerResearch

“Hard to drug is not the same as undruggable” So many pearls in discussion today of NETTER-2 and glecirasib in PDAC studies by Dr. jordan berlin. Finished with a call to “stand up & insist on lower prices” of drugs for patients. 🔥 #GI24 #PatientAdvocate

ASCO #GI24 wrap-up summary for Signatera #ctDNA data presented. Outcomes reported for > 6000 patients using Signatera across 14 studies, including 2 oral presentations and 9 independently submitted studies. Here are the highlights collated based on indication and utility👇 1/9

Henry Stitzel presenting our initial 18 month experience of #HAI at #ACT2024. 25 patients, 100% technical success, 96% initiated FUDR, and 96% with dz control/response. Not possible without Eva Selfridge Ronald A Charles, MD Jennifer Miller-Ocuin, MD DaveDietzMD Meagan costedio Emily Steinhagen! 🙏🏻

No Tweeter >1 yr & enjoyed it 😊. Congrats to @OHSUsurgery resident Issac Schwantes on Society of Surgical Oncology 🗣️ on OHSU Knight Cancer Institute Modified #HAI Dose Reduction. Only safe outcomes in ⬆️📈HAI centers will 🛑 repeating the history of HAI. Modified HAI FUDR dosing: it’s a marathon, not a sprint.

2 years ago today, I had the honor of watching my HAI partner in crime implant our program's first pump. The journey has not been easy, but I am so grateful to be able to offer this therapy to our patients & am grateful to have Lee M. Ocuin MD, FACS as my partner. Happy pumpiversary!

Prelim safety/efficacy Cue Biopharma PhI dose-expansion of CUE-102 Immuno-STAT #IL2 immunotherapy in #WT1 positive #mCRC #GI tumors presented by Nataliya Uboha Eva Selfridge #ASCO24 Check out abstr # 3553 Poster Bd # 216 6/1/24 Hall A 1:30 pm CDT meetings.asco.org/abstracts-pres…